Anirban Maitra Shares Preclinical Study Showing HCQ Inhibits MPO and Reduces NETs
Anirban Maitra, Scientific Director of Sheikh Ahmed Center for Pancreatic Cancer Research and Professor of Pathology and Translational Molecular Pathology at The University of Texas MD Anderson Cancer Center, shared a post on X about recent paper by Britney Niemann et al., published in Journal of Inflammation.
“Hydroxychloroquine reduces metastatic tumor burden in Pancreatic Cancer through myeloperoxidase (MPO) inhibition.
This preclinical study shows HCQ binds to and inhibits the enzyme MPO which diminishes neutrophil extracellular traps or NET formation.
In patient neutrophil samples tested ex vivo, HCQ can diminish MPO activity. A trial testing this premise can be conducted in adjuvant setting after Pancreatic Cancer surgery, as prevention of NET formation might delay or prevent distant (liver) recurrence.”
Title: Hydroxychloroquine reduces metastatic tumor burden in pancreatic adenocarcinoma through myeloperoxidase inhibition
Authors: Britney Niemann, Pavan Rao, Quinn Hopen, Kaitlyn Landreth, Angisha Basnet, Werner Geldenhuys, Tracy W. Liu, Brian A. Boone
Read The Full Article at Journal of Inflammation.
More posts featuring Anirban Maitra on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023